牛牛AI助理已提取核心訊息
On February 2, 2024, ProSomnus, Inc., a Delaware corporation, filed a post-effective amendment to its Form S-1 on Form S-3 with the Securities and Exchange Commission (SEC). This amendment is intended to convert the original registration statement into a registration statement on Form S-3 and to remove from registration the Convertible Note Shares that were previously registered, of which 230,494 have been sold. The company is also preparing for the primary offering of up to 6,512,087 shares of common stock upon the exercise of warrants, and a secondary offering of up to 9,850,363 shares of common stock and up to 2,411,848 warrants. ProSomnus, Inc. is known for manufacturing precision, mass-customized oral appliance therapy devices to treat obstructive sleep apnea. The company's common stock...Show More
On February 2, 2024, ProSomnus, Inc., a Delaware corporation, filed a post-effective amendment to its Form S-1 on Form S-3 with the Securities and Exchange Commission (SEC). This amendment is intended to convert the original registration statement into a registration statement on Form S-3 and to remove from registration the Convertible Note Shares that were previously registered, of which 230,494 have been sold. The company is also preparing for the primary offering of up to 6,512,087 shares of common stock upon the exercise of warrants, and a secondary offering of up to 9,850,363 shares of common stock and up to 2,411,848 warrants. ProSomnus, Inc. is known for manufacturing precision, mass-customized oral appliance therapy devices to treat obstructive sleep apnea. The company's common stock and public warrants are listed on the Nasdaq Global Market and Nasdaq Capital Market under the symbols 'OSA' and 'OSAAW', respectively. The closing prices for the common stock and public warrants as of January 29, 2024, were $0.82 and $0.035, respectively. ProSomnus has declared itself as an 'emerging growth company' and a 'smaller reporting company', which may allow it to comply with reduced public company reporting requirements for this and future filings.
2024年2月2日，特拉華州的一家公司ProSomnus, Inc. 向美國證券交易委員會（SEC）提交了S-3表格S-1的生效後修正案。該修正案旨在將原始註冊聲明轉換爲S-3表格的註冊聲明，並將先前註冊的可轉換票據股票從註冊中刪除，其中230,494股已出售。該公司還準備在行使認股權證時首次發行最多6,512,087股普通股，以及二次發行最多9,850,363股普通股和最多2,411,848份認股權證。Prosomnus, Inc. 以製造用於治療阻塞性睡眠呼吸暫停的精密、大規模定製的口服器械治療設備而聞名。該公司的普通股和公開認股權證分別在納斯達克全球市場和納斯達克資本市場上市，代碼分別爲...展開全部
2024年2月2日，特拉華州的一家公司ProSomnus, Inc. 向美國證券交易委員會（SEC）提交了S-3表格S-1的生效後修正案。該修正案旨在將原始註冊聲明轉換爲S-3表格的註冊聲明，並將先前註冊的可轉換票據股票從註冊中刪除，其中230,494股已出售。該公司還準備在行使認股權證時首次發行最多6,512,087股普通股，以及二次發行最多9,850,363股普通股和最多2,411,848份認股權證。Prosomnus, Inc. 以製造用於治療阻塞性睡眠呼吸暫停的精密、大規模定製的口服器械治療設備而聞名。該公司的普通股和公開認股權證分別在納斯達克全球市場和納斯達克資本市場上市，代碼分別爲 “OSA” 和 “OSAAW”。截至2024年1月29日，普通股和公開認股權證的收盤價分別爲0.82美元和0.035美元。ProsomNus已宣佈自己爲 “新興成長型公司” 和 “小型申報公司”，這可能使其能夠遵守降低的上市公司在本次和未來申報中的報告要求。
有用
沒用
